ICOVIR-7

AXP000051.1 · Oncolytic virus

Platform
adenovirus (Ad5, modified E2F-1 promoter with extra E2F sites, Delta-24, RGD fiber)
Originator
IDIBELL / Institut Catala d'Oncologia (Ramon Alemany)

Names

NameTypeSource
ICOVIR-7preferred name, codecurator, paper

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (ICOVIR-7)
Replication
conditionally replicating
Modifications
E2F-1 promoter with four extra E2F binding sites; E1A-Delta24; RGD-4C fiber
Route
intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 20501623Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research2010name in title: ICOVIR-7

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 19710704A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.Gene therapy2009name in abstract: ICOVIR-7

Notes

Given to 21 patients with advanced solid tumours in Finland under the Advanced Therapy Access Program (ATAP), an individualised-treatment programme rather than a registered clinical trial (Nokisalmi et al., Clin Cancer Res 2010). No registered trial found.

How to cite

ICOVIR-7 (AXP000051.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000051.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.